UB Paderborn / Katalog / Suche / in CDI

Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

The New England journal of medicine, 2004-04, Vol.350 (15), p.1505-1515

2004

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials

Therapeutic innovation & regulatory science, 2008-07, Vol.42 (4), p.303-319

2008

Link zum Volltext

Verfügbarkeit prüfen

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion

Arteriosclerosis, thrombosis, and vascular biology, 2005-05, Vol.25 (5), p.1057

2005

Link zum Volltext

Verfügbarkeit prüfen

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1111-1120

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study

Diabetes, obesity & metabolism, 2018-03, Vol.20 (3), p.530-540

2018

Link zum Volltext

Verfügbarkeit prüfen

Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts

Therapeutic innovation & regulatory science, 2024-01, Vol.58 (1), p.114-126

2024

Link zum Volltext

Verfügbarkeit prüfen

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

Diabetes therapy, 2018-02, Vol.9 (1), p.49-66

2018

Link zum Volltext

Verfügbarkeit prüfen

865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Current medical research and opinion, 2019-08, Vol.35 (8), p.1335-1343

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

Diabetologia, 2020-06, Vol.63 (6), p.1128-1140

2020

Link zum Volltext

Verfügbarkeit prüfen

859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Diabetes therapy, 2018-02, Vol.9 (1), p.193-207

2018

Link zum Volltext

Verfügbarkeit prüfen

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

European heart journal, 2023-12, Vol.44 (48), p.5163-5166

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

Current medical research and opinion, 2020-08, Vol.36 (8), p.1277-1284

2020

Link zum Volltext

Verfügbarkeit prüfen

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

Diabetes therapy, 2018-02, Vol.9 (1), p.253-268

2018

Link zum Volltext

Verfügbarkeit prüfen

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial

Annals of internal medicine, 2009-02, Vol.150 (4), p.255

2009

Link zum Volltext

Verfügbarkeit prüfen

481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV

Diabetes, obesity & metabolism, 2022-07, Vol.24 (7), p.1245-1254

2022

Link zum Volltext

Verfügbarkeit prüfen

2353-PUB: Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Sleep & breathing, 2023-05, Vol.27 (2), p.669-672

2023

Link zum Volltext

Verfügbarkeit prüfen

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

Circulation (New York, N.Y.), 2022-08, Vol.146 (8), p.652-654

2022

Link zum Volltext

Verfügbarkeit prüfen

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1398-1402

2023

Link zum Volltext

Verfügbarkeit prüfen

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

Current medical research and opinion, 2020-07, Vol.36 (7), p.1097-1106

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study

Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial

481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV

2353-PUB: Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

Suchergebnisse filtern